



# LASA SUPERGENERICS LIMITED

Correspondence Office : B/207, "CITI POINT", Near Kohinoor Hotel, J. B. Nagar,  
Andheri (E), Mumbai - 400059 Tel. : +91 22 4970 1092

Ref. No.: LASA/SE/17-18/050

Monday February 12, 2018

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
---	---

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held today i.e. February 12, 2018**

The Board meeting of the Company commenced today at 2 p.m. and concluded with a vote of thanks to the Chair at 4.30 p.m. The following are some of the important items of agenda which were discussed and approved at the meeting:

**Approved Statement of Unaudited Financial Results for the Quarter ended December 31<sup>st</sup>, 2017.**

Further to our letter dated February 02, 2017 vide Ref. No.: LASA/SE/17-18/045 we enclose herewith statement of unaudited Financial Results for the quarter ended December 31, 2017 along with Limited Review Report submitted by the Statutory Auditors of the Company.

**Considered and approved appointment of Mr. Vishnu Gupta (DIN: 08039750) Additional Director in the capacity of Whole Time Director of the company with immediate effect i.e February 12, 2018.**

**Brief Profile of Mr. Vishnu Gupta**

He is having over 26 years' experience in Supply Chain Management, HR & Administration, Commercial, Sourcing and Procurement. Wide experience in spearheading the implementation of ERP Package with key focus on aligning the resources for compliance of required production volumes with the best possible productivity norms

**Considered and approved appointment of Ms. Manali Bhagtani (DIN: 08067867) as an Additional Director in the capacity of Independent Director of the company with immediate effect i.e February 12, 2018.**

CIN : U24233MH2016PLC274202

Brief Profile of Ms. Manali Bhaqtani

She is a practising chartered accountant, proprietor of a firm based at Mumbai in the name of M R Bhaqtani & Co., Chartered Accountants. Her area of expertise includes direct, indirect & international taxation; financial reporting, financial planning, audits, etc. She has rich exposure in Taxation, Valuation matters.

Request you to take the same on record and acknowledge receipt.

Thanking You  
Yours Sincerely,

For Lasa Supergenerics Limited

  
Hitesh Wadhvani  
Company Secretary



Encl: As above


Statement of Unaudited Financial Results for the Quarter / Nine Months Period ended 31st December, 2017

Particulars	Quarter ended		Nine Months Ended
	31.12.2017 (Unaudited)	30.09.2017 (Unaudited)	31.12.2017 (Unaudited)
<b>1. INCOME</b>			
a. Revenue from Operations	6,098.61	6,453.07	18,652.70
b. Other Income	20.03	135.21	285.11
<b>Total Income</b>	<b>6,118.64</b>	<b>6,588.28</b>	<b>18,937.81</b>
<b>2. Expenses</b>			
a. Cost of Materials consumed	3,436.60	5,209.43	11,801.77
b. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	629.63	(938.45)	226.52
c. Excise Duty on Sales	-	-	231.29
d. Employee benefits expenses	259.93	256.82	754.23
e. Finance costs	377.22	242.19	872.80
f. Depreciation & amortizations expenses	440.71	609.11	1,291.34
g. Other Expenses	424.10	621.65	1,456.18
<b>Total Expenses (a to g)</b>	<b>5,568.18</b>	<b>6,000.75</b>	<b>16,634.12</b>
Exceptional Items	-	-	-
<b>3. Profit / (Loss) before tax (1-2)</b>	<b>550.46</b>	<b>587.54</b>	<b>2,303.69</b>
<b>4. Tax expense</b>			
Current Tax	147.86	119.58	509.76
Deferred Tax	91.20	(398.42)	(89.10)
Short income tax provision for earlier years	-	-	1.73
<b>5. Net Profit / (Loss) after tax (3-4)</b>	<b>311.40</b>	<b>866.37</b>	<b>1,881.31</b>
<b>6. Other Comprehensive Income</b>			
<i>Items that will not be reclassified into Profit or Loss</i>			
Remeasurement of Defined Benefit Plans (Net of tax)	(0.22)	(0.36)	(1.32)
<b>7. Total Comprehensive Income for the year (after tax) (5+6)</b>	<b>311.19</b>	<b>866.01</b>	<b>1,879.99</b>
<b>8. Paid-up Equity Share Capital (Face Value of Re. 10 /- each)</b>	<b>2,286.44</b>	<b>2,286.44</b>	<b>2,286.44</b>
<b>9. Earnings per Equity Share (of Rs. 10/- each)</b>			
(a) Basic	1.36	3.79	8.23
(b) Diluted	1.36	3.79	8.23
See accompanying Notes to the Financial Results			


Notes :

- 1) The Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2017, were reviewed by the audit committee and approved by the board of directors in their respective meetings held on 12th February, 2018. The Statutory Auditors of the company have reviewed the said Results.
- 2) The Financial Results are prepared in compliance with Indian Accounting Standards (Ind-AS) subsequent to its adoption as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. These restated results have not been subjected to Limited Review, however, the Management has exercised due diligence to ensure that the Financial Results present a true and fair view of its affairs.
- 3) The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Monday, February 12th, 2018.
- 4) The Statutory Auditors of the Company have carried out a "Limited Review" of the above Financial Results for the Quarter and Nine Months ended December 31st, 2017.
- 5) The Company has only one reportable segment i.e. Veterinary Active Pharmaceutical Ingredients.
- 6) The format of unaudited quarterly and nine months results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's circular CIR/CFD/FAC/62/2016 dated 5th July, 2016 and SEBI clarification to disclose 'Income from Operations' inclusive of excise duty Ind AS and Schedule III to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS
- 9) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

Place : Mumbai  
Date : 12.02.2018



For Lasa Supergenerics Limited

  
**Omkar Herlekar**  
Chairman & Managing Director  
(DIN No. 01587154)



**SHAH & KATHARIYA**  
Chartered Accountants

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

To the Board of Directors of Lasa Supergenerics Limited

We have reviewed the accompanying Statement of Unaudited Financial Results ("the statement") of Lasa Supergenerics Limited ('the Company') for the quarter and nine months ended 31 December 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016.


This Statement which is the responsibility of the Company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34-"Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements, prepared in accordance with the applicable Indian Accounting Standards and other accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed or that it contains any material misstatement.

For Shah & Kathariya  
Chartered Accountants  
Firm Registration No: 115171W

Per P M Kathariya  
Partner  
Membership No: 031315



Place: Mumbai  
Date: 12 February, 2018